Literature DB >> 19015136

Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice.

Jian Guo1, Ilze Bot, Ramon de Nooijer, Sandra J Hoffman, George B Stroup, Erik A L Biessen, G Martin Benson, Pieter H E Groot, Miranda Van Eck, Theo J C Van Berkel.   

Abstract

AIMS: Cathepsin K (CatK), an established drug target for osteoporosis, has been reported to be upregulated in atherosclerotic lesions. Due to its proteolytic activity, CatK may influence the atherosclerotic lesion composition and stability. In this study, we investigated the potential role of leucocyte CatK in atherosclerotic plaque remodelling. METHODS AND
RESULTS: To assess the biological role of leucocyte CatK, we used the technique of bone marrow transplantation to selectively disrupt CatK in the haematopoietic system. Total bone marrow progenitor cells from CatK(+/+), CatK(+/-), and CatK(-/-) mice were transplanted into X-ray irradiated low-density lipoprotein receptor knockout (LDLr(-/-)) mice. The selective silencing of leucocyte CatK resulted in phenotypic changes in bone formation with an increased total bone mineral density in the CatK(-/-) chimeras and an effect of gene dosage. The absence of leucocyte CatK resulted in dramatically decreased collagen and increased macrophage content of the atherosclerotic lesions while lesion size was not affected. The atherosclerotic lesions also demonstrated less elastic lamina fragmentation and a significant increase in the apoptotic and necrotic area in plaques of mice transplanted with CatK(-/-) bone marrow.
CONCLUSION: Leucocyte CatK is an important determinant of atherosclerotic plaque composition, vulnerability, and bone remodelling, rendering CatK an attractive target for pharmaceutical modulation in atherosclerosis and osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015136     DOI: 10.1093/cvr/cvn311

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  11 in total

Review 1.  Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.

Authors:  Aline G Costa; Natalie E Cusano; Barbara C Silva; Serge Cremers; John P Bilezikian
Journal:  Nat Rev Rheumatol       Date:  2011-06-14       Impact factor: 20.543

2.  Cysteine Protease Cathepsins in Atherosclerosis and Abdominal Aortic Aneurysm.

Authors:  Sara Sjöberg; Guo-Ping Shi
Journal:  Clin Rev Bone Miner Metab       Date:  2011-06-18

3.  Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro.

Authors:  Yaongamphi Vashum; Riya Premsingh; Amuthavalli Kottaiswamy; Mathangi Soma; Abirami Padmanaban; Parkavi Kalaiselvan; Shila Samuel
Journal:  Mol Biol Rep       Date:  2020-12-08       Impact factor: 2.316

4.  Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?

Authors:  Izabela Podgorski
Journal:  Future Med Chem       Date:  2009-04       Impact factor: 3.808

5.  Local effects of human PCSK9 on the atherosclerotic lesion.

Authors:  Ilaria Giunzioni; Hagai Tavori; Roman Covarrubias; Amy S Major; Lei Ding; Youmin Zhang; Rachel M DeVay; Liang Hong; Daping Fan; Irene M Predazzi; Shirya Rashid; MacRae F Linton; Sergio Fazio
Journal:  J Pathol       Date:  2015-11-13       Impact factor: 7.996

6.  Cathepsin K activity controls injury-related vascular repair in mice.

Authors:  Lina Hu; Xian Wu Cheng; Haizhen Song; Aiko Inoue; Haiying Jiang; Xiang Li; Guo-Ping Shi; Eiji Kozawa; Kenji Okumura; Masafumi Kuzuya
Journal:  Hypertension       Date:  2013-12-16       Impact factor: 10.190

7.  Mannose receptor 2 attenuates renal fibrosis.

Authors:  Jesús M López-Guisa; Xiaohe Cai; Sarah J Collins; Ikuyo Yamaguchi; Daryl M Okamura; Thomas H Bugge; Clare M Isacke; Claire L Emson; Scott M Turner; Stuart J Shankland; Allison A Eddy
Journal:  J Am Soc Nephrol       Date:  2011-11-17       Impact factor: 10.121

Review 8.  The Roles of CD137 Signaling in Atherosclerosis.

Authors:  In-Hyuk Jung; Goo Taeg Oh
Journal:  Korean Circ J       Date:  2016-10-20       Impact factor: 3.243

Review 9.  PCSK9 and Atherosclerosis - Lipids and Beyond.

Authors:  Michael D Shapiro; Sergio Fazio
Journal:  J Atheroscler Thromb       Date:  2017-03-09       Impact factor: 4.928

Review 10.  Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review.

Authors:  Na-Qiong Wu; Hui-Wei Shi; Jian-Jun Li
Journal:  Front Cardiovasc Med       Date:  2022-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.